{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:57:44Z","timestamp":1787338664133,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular events in statin-treated patients with first acute ischemic stroke (AIS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who were admitted to the hospital with first AIS from October 2018 to September 2020 were eligible for inclusion. Correlation between the change of Lp(a) levels and potential influencing factors was assessed by linear regression analysis. Cox proportional regression models were used to estimate the association between Lp(a) and recurrent vascular events including AIS, transient ischemic attack, myocardial infarction and coronary revascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 303 patients, 69.6% males with mean age 64.26 \u00b1 11.38 years, completed the follow-up. During the follow-up period, Lp(a) levels increased in 50.5% of statin-treated patients and the mean percent change of Lp(a) levels were 14.48% (95% CI 6.35\u201322.61%). Creatinine (\u03b2 = 0.152, 95% CI 0.125\u20130.791,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.007) and aspartate aminotransferase (AST) (\u03b2 = 0.160, 95% CI 0.175\u20130.949,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005) were positively associated with the percent change of Lp(a) levels. During a median follow-up of 26 months, 66 (21.8%) patients had a recurrent vascular event. The median time period between AIS onset and vascular events recurrence was 9.5 months (IQR 2.0\u201316.3 months). The on-statin Lp(a) level \u226570 mg\/dL (HR 2.539, 95% CI 1.076\u20135.990,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.033) and the change of Lp(a) levels (HR 1.003, 95% CI 1.000\u20131.005,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.033) were associated with the recurrent vascular events in statin-treated patients with first AIS. Furthermore, the on-statin Lp(a) levels \u226570 mg\/dL (HR 3.612, 95% CI 1.018\u201312.815,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.047) increased the risk of recurrent vascular events in patients with low-density lipoprotein cholesterol (LDL-C) levels &amp;lt; 1.8 mmol\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lp(a) levels increased in half of statin-treated patients with first AIS. Creatinine and AST were positively associated with the percent change of Lp(a) levels. Lp(a) is a determinant of residual vascular risk and the change of Lp(a) is positively associated with the risk of recurrent vascular events in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.1004264","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T01:16:45Z","timestamp":1667438205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lanjing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e051121189015","DOI":"10.2174\/1573403X16999201210200342","article-title":"Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review","volume":"17","author":"Alloubani","year":"2021","journal-title":"Curr Cardiol Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5853\/jos.2018.00787","article-title":"Updates on prevention of hemorrhagic and lacunar strokes","volume":"20","author":"Tsai","year":"2018","journal-title":"J Stroke."},{"key":"B4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.12.018","article-title":"Management of residual risk after statin therapy","volume":"245","author":"Reith","year":"2016","journal-title":"Atherosclerosis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","article-title":"Statin drug interactions and related adverse reactions: an update","volume":"17","author":"Bellosta","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drug Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.acvd.2021.10.009","article-title":"Lipoprotein(a): pathophysiology, measurement, indication and treatment in cardiovascular disease. a consensus statement from the nouvelle soci\u00e9t\u00e9 francophone d'ath\u00e9roscl\u00e9rose (NSFA)","volume":"114","author":"Durlach","year":"2021","journal-title":"Arch Cardiovasc Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/cvr\/cvab100","article-title":"Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics","volume":"118","author":"Swerdlow","year":"2022","journal-title":"Cardiovasc Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.5551\/jat.RV17034","article-title":"Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease","volume":"26","author":"Tada","year":"2019","journal-title":"J Atheroscler Thromb."},{"key":"B13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.hjc.2020.09.016","article-title":"The role of Lipoprotein(a) in cardiovascular disease: current concepts and future perspectives","volume":"61","author":"Vavuranakis","year":"2020","journal-title":"Hellenic J Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the regards study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/HCO.0b013e32832ac21a","article-title":"Lipoprotein a: where are we now?","volume":"24","author":"Tziomalos","year":"2009","journal-title":"Curr Opin Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOL.0000000000000681","article-title":"Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?","volume":"31","author":"Langsted","year":"2020","journal-title":"Curr Opin Lipidol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/eurheartj\/ehab875","article-title":"The year in cardiovascular medicine 2021: dyslipidaemia","volume":"43","author":"Tokgozoglu","year":"2022","journal-title":"Eur Heart J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"212609","DOI":"10.7573\/dic.212609","article-title":"Therapeutic management of hyperlipoproteinemia (a)","volume":"8","author":"Kosmas","year":"2019","journal-title":"Drugs Context."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e000722","DOI":"10.1136\/openhrt-2017-000722","article-title":"Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community","volume":"5","author":"Lieb","year":"2018","journal-title":"Open Heart."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation."},{"key":"B24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke."},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.amjcard.2020.12.075","article-title":"Relation of first and total recurrent atherosclerotic cardiovascular disease events to increased lipoprotein(a) levels among statin treated adults with cardiovascular disease","volume":"145","author":"Wong","year":"2021","journal-title":"Am J Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.06.202","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","author":"de Boer","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40261-013-0129-2","article-title":"Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin\/kexin type 9","volume":"33","author":"Guo","year":"2013","journal-title":"Clin Drug Investig."},{"key":"B31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1194\/jlr.M005769","article-title":"Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet","volume":"51","author":"Faghihnia","year":"2010","journal-title":"J Lipid Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J Am Soc Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e114397","DOI":"10.1371\/journal.pone.0114397","article-title":"Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hep4.1830","article-title":"Low lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"6","author":"Meroni","year":"2022","journal-title":"Hepatol Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"105689","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/ijo.2009.144","article-title":"Decrease of Lp(a) during weight reduction in obese children is modified by the apo(a) kringle-IV copy number variation","volume":"33","author":"Brandst\u00e4tter","year":"2009","journal-title":"Int J Obes."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1172\/JCI109813","article-title":"Turnover of lipoprotein (a) in man","volume":"65","author":"Krempler","year":"1980","journal-title":"J Clin Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J Lipid Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1476-511X-5-4","article-title":"Influence of liver cancer on lipid and lipoprotein metabolism","volume":"5","author":"Jiang","year":"2006","journal-title":"Lipids Health Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1185\/03007999609115228","article-title":"Lipoprotein(a) in cirrhosis. a new index of liver functions?","volume":"13","author":"Malaguarnera","year":"1996","journal-title":"Curr Med Res Opin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0009-8981(97)06533-9","article-title":"Lipoprotein (a) serum levels in patients with hepatocarcinoma","volume":"262","author":"Basili","year":"1997","journal-title":"Clin Chim Acta."},{"key":"B45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2008","journal-title":"Am J Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","article-title":"Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation","volume":"38","author":"Kronenberg","year":"1997","journal-title":"J Lipid Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1161\/STROKEAHA.116.014436","article-title":"Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke","volume":"48","author":"Lange","year":"2017","journal-title":"Stroke."},{"key":"B49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12035-016-0346-9","article-title":"Lipoprotein (a) as a predictor of early stroke recurrence in acute ischemic stroke","volume":"55","author":"Hong","year":"2018","journal-title":"Mol Neurobiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur Heart J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","article-title":"Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease","volume":"13","author":"Moriarty","year":"2019","journal-title":"J Clin Lipidol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01060-4","article-title":"Lp(a): a new pathway to target?","author":"Nurmohamed","year":"2022","journal-title":"Curr Atheroscler Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2022.5333","article-title":"The potential clinical benefit of lowering lipoprotein(a)","volume":"327","author":"Ference","year":"2022","journal-title":"JAMA."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1004264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T01:16:48Z","timestamp":1667438208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1004264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":57,"alternative-id":["10.3389\/fneur.2022.1004264"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1004264","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"article-number":"1004264"}}